PDF(863 KB)
Clinical and molecular characteristics of neonatal Klebsiella pneumoniae sepsis
Hebei Provincial Neonatal Sepsis Research Collaboration Group
Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (3) : 269-276.
PDF(863 KB)
PDF(863 KB)
Clinical and molecular characteristics of neonatal Klebsiella pneumoniae sepsis
Objective To characterize the molecular profiles of Klebsiella pneumoniae isolates causing neonatal sepsis and assess their clinical implications. Methods Clinical data and bloodstream isolates from neonates with Klebsiella pneumoniae sepsis admitted to four hospitals in Hebei Province from 2020 to 2024 were collected. Whole-genome sequencing was performed to analyze molecular characteristics of the pathogenic strains. Clinical features were compared between virulence gene-carrying and non-carrying groups. A phylogenetic tree based on sequencing data was constructed to explore potential transmission routes. Results A total of 37 infants and their clinical bloodstream isolates were included. Thirty-three (89%) had late-onset infection, and 32 (86%) were hospital-acquired. Preterm infants accounted for 95%. Twenty-eight (76%) underwent invasive procedures, and 13 (35%) had prior exposure to broad-spectrum antimicrobials. All infants were cured after treatment. Resistance rates to third-generation cephalosporins and carbapenems were 89% and 27%, respectively. ST45 was the most common sequence type. The carriage rates of extended-spectrum β-lactamase and carbapenemase genes were 84% and 24%, respectively. Concordance between resistance genes and phenotypic resistance was 86%. Clinical antimicrobial use was not fully consistent with resistance phenotypes or gene carriage. Among virulence genes, ybt had the highest carriage rate (54%). The proportion of concurrent infections at other sites did not differ significantly between the virulence gene-carrying and non-carrying groups (50% vs 29%, P=0.315). Phylogenetic analysis revealed intra-hospital and inter-hospital transmission of Klebsiella pneumoniae strains causing neonatal sepsis. Conclusions Detection of antimicrobial resistance and virulence genes facilitates deeper understanding of bacterial pathogenesis and provides a basis for optimizing regional infection control and antimicrobial treatment strategies.
Neonatal sepsis / Klebsiella pneumoniae / Whole-genome sequencing / Multidrug resistance
| [1] |
全国细菌耐药监测网. 2023年全国细菌耐药监测报告(简要版)[EB/OL]. (2024-11-18)[2025-04-12].
|
| [2] |
World Health Organization. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance[EB/OL]. (2024-05-17)[2025-04-20].
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
Investigators of the Delhi Neonatal Infection Study (DeNIS) Collaboration. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study[J]. Lancet Glob Health, 2016, 4(10): e752-e760. DOI: 10.1016/S2214-109X(16)30148-6 .
|
| [9] |
河北新生儿败血症研究协作组. 中国河北省新生儿败血症病原体构成及耐药性的横断面研究[J]. 中国当代儿科杂志, 2024, 26(4): 350-357. PMCID: PMC11057296. DOI: 10.7499/j.issn.1008-8830.2309107 .
|
| [10] |
中华医学会儿科学分会新生儿学组, 中华儿科杂志编辑委员会. 新生儿败血症诊断与治疗专家共识(2024)[J]. 中华儿科杂志, 2024, 62(10): 931-940. DOI: 10.3760/cma.j.cn112140-20240505-00307 .
|
| [11] |
中华人民共和国国家卫生和计划生育委员会. 临床微生物实验室血培养操作规范: WS/T 503-2017 [S]. 北京: 中国标准出版社, 2017.
|
| [12] |
CLSI. Performance standards for antimicrobial susceptibility testing: M100 31st edition [S]. Malvern, PA, USA: CLSI, 2021.
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
史梦兰, 李文茹, 谢小保. 临床肺炎克雷伯菌的异质性耐药研究进展[J]. 微生物学通报, 2024, 51(7): 2326-2336. DOI: 10.13344/j.microbiol.china.230482 .
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
中国老年医学学会检验医学分会, 上海市医学会检验医学专科分会, 上海市微生物学会临床微生物学专业委员会. 高毒力肺炎克雷伯菌实验室检测专家共识[J]. 中华检验医学杂志, 2023, 46(11): 1164-1172. DOI: 10.3760/cma.j.cn114452-20230925-00162 .
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
所有作者声明无利益冲突。